{
    "clinical_study": {
        "@rank": "8398", 
        "acronym": "TOLERATE", 
        "arm_group": {
            "arm_group_label": "BG00012 (Dimethyl fumarate) 240 mg BID", 
            "arm_group_type": "Experimental", 
            "description": "BG00012 administered at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter for a total of 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the effect of symptomatic therapies on\n      gastrointestinal-related events reported by subjects with relapsing-remitting multiple\n      sclerosis initiating therapy with BG00012 (dimethyl fumarate, DMF) in the clinical practice\n      setting.\n\n      The secondary objectives of this study in this study population are as follows: To evaluate\n      gastrointestinal-related events requiring symptomatic therapy and the role of those\n      therapies over time;  To evaluate gastrointestinal-related events that lead to a physician's\n      decision to manage the events with BG00012 dose modification; and To evaluate\n      gastrointestinal-related events that lead to BG00012 discontinuation after the use of\n      symptomatic therapy."
        }, 
        "brief_title": "Gastrointestinal Tolerability Study Of Dimethyl Fumarate (DMF) In Participants With Relapsing-Remitting Multiple Sclerosis In Germany", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsing-Remitting Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Have a confirmed diagnosis of relapsing-remitting multiple sclerosis (RRMS) according\n             to the current McDonald Criteria and satisfy the therapeutic indication as described\n             in the official local registration for Tecfidera (dimethyl fumarate).\n\n          -  Na\u00efve to dimethyl fumarate (DMF) and fumaric acid esters.\n\n        Key Exclusion Criteria:\n\n          -  Female subjects who are currently pregnant or breastfeeding or who are considering\n             becoming pregnant while in the study\n\n          -  History of significant gastrointestinal disease (e.g., irritable bowel disease,\n             peptic ulcer disease, history of major gastrointestinal surgeries), or chronic use of\n             gastrointestinal -related symptomatic therapy as determined by the Investigator (or\n             \u22657 consecutive days of gastrointestinal -related symptomatic therapy\n\n          -  Known active malignancies\n\n          -  History of anaphylaxis or severe allergic reactions or known drug hypersensitivity\n\n          -  Current use of B vitamin supplements\n\n          -  In the opinion of the Investigator, blood test values suggestive of a low lymphocyte\n             count or renal or hepatic impairment, as described in the product label precautions\n             for use.\n\n        NOTE:  Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "230", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125604", 
            "org_study_id": "109MS407", 
            "secondary_id": "2013-001486-17"
        }, 
        "intervention": {
            "arm_group_label": "BG00012 (Dimethyl fumarate) 240 mg BID", 
            "description": "BG00012 capsules taken orally with food or within one hour of a meal. BG00012 is administered at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter for a total of 12 weeks. Dose modifications are allowed as described in the product label.", 
            "intervention_name": "BG00012", 
            "intervention_type": "Drug", 
            "other_name": [
                "Tecfidera\u2122", 
                "DMF", 
                "Dimethyl fumarate"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Dimethyl fumarate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Gastrointestinal event", 
        "lastchanged_date": "April 25, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects With Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate", 
        "overall_contact": {
            "email": "clinicaltrials@biogenidec.com", 
            "last_name": "Biogen Idec"
        }, 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Gastrointestinal-related events as measured by the Modified Overall Gastrointestinal Symptom Scale (MOGISS) and Modified Acute Gastrointestinal Symptom Scale (MAGISS)", 
                "measure": "Incidence Of Gastrointestinal-Related Events In Participants Who Utilize Symptomatic Therapy During The 12-Week Treatment Period", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 12"
            }, 
            {
                "measure": "Severity Of Gastrointestinal -Related Events In Participants Who Utilize Symptomatic Therapy During The 12-Week Treatment Period", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 12"
            }, 
            {
                "measure": "Duration Of Gastrointestinal -Related Events In Participants Who Utilize Symptomatic Therapy During The 12-Week Treatment Period", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125604"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage Of Participants Requiring Gastrointestinal Symptomatic Therapy During The 12-Week Treatment Period", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 12"
            }, 
            {
                "measure": "Number of Participants Who Used Symptomatic Therapies for Gastrointestinal -Related Events During the 12-Week Treatment Period", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 12"
            }, 
            {
                "measure": "Duration of Use of Symptomatic Therapies for Gastrointestinal -Related Events During the 12-Week Treatment Period", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 12"
            }, 
            {
                "measure": "Kaplan-Meier Estimates for the Proportion of Participants Who Require BG00012 Dose Reduction In Response To Gastrointestinal -Related Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 12"
            }, 
            {
                "measure": "The Percentage of Participants Who Discontinue BG00012 Due To Gastrointestinal -Related Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 12"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}